Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Santhera Pharmaceuticals Holding AG EBITDA Margin % Related Terms
Santhera Pharmaceuticals Holding AG EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EBITDA Margin % Chart
SPHDF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a EBITDA Margin % of -1.31% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #435 out of 945 companies in the Biotechnology industry, placing it in the top 46%.
Is Santhera Pharmaceuticals Holding AG's EBITDA Margin % too high?
Santhera Pharmaceuticals Holding AG's current EBITDA Margin % is -1.31%. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #435 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #435 out of 945 companies for EBITDA Margin %. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current EBITDA Margin % is -1.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current EBITDA Margin % is -1.31%. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current EBITDA Margin % is -1.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.
Key valuation signals for SPHDF:
EBITDA Margin %: -1.31%
GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
